KatieB Posted January 18, 2019 Share Posted January 18, 2019 FDA has accepted the supplemental Biologics License Application (sBLA) for Tecentriq in combination with chemotherapy for the first-line treatment of people with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. https://www.gene.com/media/press-releases/14773/2019-01-16/fda-accepts-genentechs-supplemental-biol Roz and Tom Galli 2 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.